Key Highlights

  • The board declared an $0.08 regular quarterly Dividend on July 23, 2026, payable October 15 to record holders.
  • Second-quarter GAAP net loss was $186.6 million, or $1.49 per diluted share, compared with Net Income of $0.53 per share.
  • Adjusted EPS, a non-GAAP measure, was $0.26, compared with $0.69 in the second quarter of 2025.
  • Full-year 2026 adjusted EPS guidance is $1.19-$1.49, and free Cash Flow guidance is $75 million to $225 million.

Overview

FMC Corporation (NYSE:FMC) declared an $0.08 regular quarterly dividend on July 23, 2026, payable October 15 to holders of record on September 30. The dividend yields 3.34%. Second-quarter GAAP diluted EPS was a loss of $1.49, and adjusted EPS, a non-GAAP measure, was $0.26. Cash from operations was $363 million.

Dividend Program and Shareholder Returns

The board declared a regular quarterly dividend of $0.08 per share on July 23, 2026, payable October 15 to shareholders of record on September 30. It trades ex-dividend on September 30.

The company describes the dividend as a regular quarterly dividend. Full-year free cash flow guidance of $75 million to $225 million includes the $200 million upfront rimisoxafen licensing payment. Each dividend remains subject to board approval.

About the Company

FMC Corporation is a global agricultural sciences company that develops and sells crop protection products. It reports GAAP results alongside adjusted EBITDA and adjusted EPS, both non-GAAP measures, and reports Revenue excluding its India commercial business.

Second-Quarter Revenue, Earnings and Guidance

Second-quarter revenue was $867 million, down 17% from a year earlier, and $841 million excluding India, down 20%. The GAAP net loss was $186.6 million, or $1.49 per diluted share, compared with net income of $66.7 million, or $0.53.

Adjusted EBITDA, a non-GAAP measure, was $153 million, down 26%. Adjusted EPS was $0.26, down 62% from $0.69.

Full-year 2026 guidance is revenue excluding India of $3.50-$3.70 billion, adjusted EBITDA of $620-$680 million, adjusted EPS of $1.19-$1.49 and free cash flow of $75-$225 million. The company states these represent declines of 7%, 23% and 55% at the midpoints for revenue excluding India, adjusted EBITDA and adjusted EPS.

Volume and Price Pressure, Cash Flow and Debt Reduction

The company stated that volumes declined 10% because of lower diamide partner orders and reduced Demand for core legacy products, particularly in North America. Price declined 7%, driven by pressure on core legacy products and planned Rynaxypyr active pricing actions.

Cash from operations was $363 million, an increase of $297 million versus 2025, including the $200 million upfront payment. Free cash flow was $357 million, an improvement of $318 million. At June 30, cash was $476.6 million and total debt was $4,280.6 million.

The debt reduction actions announced were the $252 million sale of the India commercial business, the $200 million rimisoxafen licensing agreement, a $114 million Newark sale-leaseback and a $400 million Tessenderlo Group Equity investment. The chief executive stated that the strategic review is concluded.

Outlook

Adjusted EPS relative to the $1.19-$1.49 guidance range, free cash flow relative to the $75-$225 million range, Volume and price trends, total debt, and the board's quarterly declarations are the relevant considerations.